Related Experiment Video

Updated: Jul 19, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

New chemotherapy regimens for metastatic bladder cancer

P M Dodd1, D F Bajorin

  • 1Medical Oncology-Hematology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.

Current Opinion in Urology
|October 14, 2006
PubMed

Insights

Metastatic transitional cell carcinoma (TCC) treatment is evolving. New chemotherapy combinations show promise, but further research is needed to confirm their survival benefits over the current standard M-VAC regimen.

Area of Science:

  • Oncology
  • Medical Chemistry

Background:

  • Methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) is the standard treatment for metastatic transitional cell carcinoma (TCC).
  • M-VAC therapy is associated with significant toxicity and limited durable disease-free survival rates.
  • There is a need for novel chemotherapeutics and combination regimens for metastatic TCC.

Purpose of the Study:

  • To review novel chemotherapeutic agents and their combinations for metastatic TCC.
  • To evaluate the potential of new agents to improve outcomes in metastatic TCC.

Main Methods:

  • Review of recent investigations and phase II trials.
  • Focus on single-agent activity and combination regimens of new chemotherapeutics.
  • Analysis of preliminary results from clinical trials.

Main Results:

  • Paclitaxel, gemcitabine, and ifosfamide are identified as highly active agents in metastatic TCC.
  • Numerous phase II trials of novel combinations have reported promising preliminary outcomes.
  • Current data suggests potential for improved efficacy with newer regimens.

Conclusions:

  • Novel chemotherapy combinations show promise for metastatic TCC treatment.
  • Further long-term follow-up and randomized trials are essential.
  • The impact of newer regimens on overall survival needs to be determined.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...